Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Genmab A/S - ADR - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
GMAB
Nasdaq
8731
https://www.genmab.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Genmab A/S - ADR
Market Chatter: Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'
- May 15th, 2024 2:13 pm
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
- May 14th, 2024 2:05 pm
Danish biotech says companies should tap into China’s ‘impressive innovation’
- May 14th, 2024 4:00 am
Transactions in Connection with Share Buy-back Program
- May 13th, 2024 2:09 pm
Capital Increase in Genmab as a Result of Employee Warrant Exercise
- May 7th, 2024 6:27 pm
Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript
- May 3rd, 2024 4:38 pm
Genmab Announces Financial Results for the First Quarter of 2024
- May 2nd, 2024 3:01 pm
Comstock Inc (LODE) Q1 2024 Earnings Call Transcript Highlights: Strategic Investments and ...
- May 1st, 2024 11:01 am
Pfizer and Genmab’s Tivdak wins full FDA approval for cervical cancer
- Apr 30th, 2024 2:02 pm
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
- Apr 29th, 2024 10:40 pm
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
- Apr 29th, 2024 10:40 pm
Transactions in Connection with Share Buy-back Program Genmab
- Apr 29th, 2024 8:24 am
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
- Apr 16th, 2024 10:24 am
Roche reports survival data for new dual-acting lymphoma drug
- Apr 15th, 2024 11:57 am
Genmab Takes The Next Step In Its 'Evolution' With A $1.8 Billion Takeover
- Apr 3rd, 2024 8:02 pm
Stocks to Watch Wednesday: Disney, Intel, Tesla, Trump Media
- Apr 3rd, 2024 5:05 pm
Genmab buys ProfoundBio for $1.8B, adding to ADC dealmaking flurry
- Apr 3rd, 2024 11:28 am
Genmab Strengthens Oncology Portfolio With $1.8 Bln Acquisition of ProfoundBio
- Apr 3rd, 2024 8:48 am
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
- Apr 3rd, 2024 5:35 am
Completion of share buy-back program
- Mar 18th, 2024 9:49 am
Scroll